Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cystine/glutamate transporter, also known as system xc−, is a sodium-independent and chloride-dependent antiporter that mediates the 1:1 exchange of extracellular cystine for intracellular glutamate across the plasma membrane. It is composed of two subunits: SLC7A11/xCT (light chain) and SLC3A2/CD98/4F2hc (heavy chain). xCT is crucial for maintaining cellular redox balance by supplying cysteine for GSH biosynthesis. It is involved in regulating synaptic activity and plays a role in various diseases, particularly cancer, where it supports tumor growth. Inhibitors like sulfasalazine and erastin are being explored for cancer therapy due to their ability to induce ferroptosis via inhibition of xCT function.
Inhibition of cystine/glutamate exchange, leading to ferroptosis
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cystine/Glutamate Transporter (xCT).